Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences

argenx (ARGX) has announced a $2.2 billion cash acquisition of Forte Biosciences (FBRX) at $77 per share, representing a substantial 40% premium to Friday's closing price. This transaction represents a market-moving M&A event that fundamentally alters shareholder value distribution between the two entities and signals strategic repositioning within the immunology and dermatology treatment space.

For FBRX shareholders, the all-cash consideration at a significant premium validates the company's therapeutic pipeline and provides liquidity certainty. The deal structure suggests ARGX management sees meaningful synergy potential or portfolio gap-filling opportunity, likely in FBRX's clinical-stage assets. Hedge fund positioning toward ARGX over FBRX (pre-announcement) may reflect confidence in the acquirer's ability to deploy capital efficiently post-close.

For ARGX, this acquisition represents a growth lever and potential revenue diversification play, though it commits significant dry powder and may pressure near-term financial metrics. The deal underscores consolidation momentum in the specialized biopharma sector as mid-cap immunology players seek scale and platform expansion.

Sector implication: Health Care consolidation accelerates, benefiting acquirers with strong balance sheets and validated platforms. The transaction reinforces investor appetite for scale-driven M&A among immunology-focused therapeutics companies, potentially triggering re-valuation of peer targets with comparable therapeutic focus.